Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works

Pattern Recognition Receptors and Inflammation

Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · see citing works

Taking dendritic cells into medicine

Steinman, R., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,243 · see citing works

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · see citing works

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · see citing works

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works

HMGB1 is a therapeutic target for sterile inflammation and infection

Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437 · see citing works

HMGB1 and RAGE in Inflammation and Cancer

Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436 · see citing works

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377 · see citing works

Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372 · see citing works

Intracellular Toll-like Receptors

Blasius, A. L., & Beutler, B. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.012 · Cited by 1,329 · see citing works

Trex1 prevents cell-intrinsic initiation of autoimmunity

Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280 · see citing works

Immunogenic and tolerogenic cell death

Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · see citing works

Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R. E., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028 · see citing works

RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III–transcribed RNA intermediate

Ablasser, A., Bauernfeind, F. G., Hartmann, G., Latz, E., Fitzgerald, K. A., & Hornung, V. (2009) · Nature Immunology · doi:10.1038/ni.1779 · Cited by 892 · see citing works

Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function

Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R. (2005) · Science · doi:10.1126/science.1113401 · Cited by 748 · see citing works

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C. Y., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 748 · see citing works

Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

Fueyo, A. S., Tian, J. Y., Picarella, D., Domenig, C. M., Zheng, X. X., Sabatos, C. A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V. K., et al. (2003) · Nature Immunology · doi:10.1038/ni987 · Cited by 713 · see citing works

Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells

Anderson, A. C., Anderson, D. E., Bregoli, L., Hastings, W. D., Kassam, N., Lei, C., Chandwaskar, R., Kármán, J., Su, E. W., Hirashima, M., et al. (2007) · Science · doi:10.1126/science.1148536 · Cited by 703 · see citing works

Mechanisms of Immune Evasion by Tumors

Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 690 · see citing works

HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses

Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., et al. (2009) · Nature · doi:10.1038/nature08512 · Cited by 683 · see citing works

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

Sabatos, C. A., Chakravarti, S., Cha, E., Schubart, A., Fueyo, A. S., Zheng, X. X., Coyle, A. J., Strom, T. B., Freeman, G. J., & Kuchroo, V. K. (2003) · Nature Immunology · doi:10.1038/ni988 · Cited by 629 · see citing works

Immune Therapy for Cancer

Dougan, M. L., & Dranoff, G. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 610 · see citing works

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 575 · see citing works

Interleukin 23 production by intestinal CD103+CD11b+ dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense

Kinnebrew, M. A., Buffie, C. G., Diehl, G. E., Zenewicz, L. A., Leiner, I., Hohl, T. M., Flavell, R. A., Littman, D. R., & Pamer, E. G. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.011 · Cited by 491 · see citing works

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

Kikushige, Y., Shima, T., Takayanagi, S., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T. T., Inagaki, Y., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.11.014 · Cited by 480 · see citing works

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

NAKAYAMA, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., Yagita∥, H., & Okumura, K. (2009) · Blood · doi:10.1182/blood-2008-10-185884 · Cited by 434 · see citing works

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells

Besch, R., Poeck, H., Hohenauer, T., Senft, D., Häcker, G. A., Berking, C., Hornung, V., Endres, S., Ruzicka, T., Rothenfußer, S., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37155 · Cited by 429 · see citing works

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387 · see citing works

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

DeKruyff, R. H., Bu, X., Ballesteros, Á., Santiago, C. A., Chim, Y.-L., Lee, H., Karisola, P., Pichavant, M., Kaplan, G. G., Umetsu, D. T., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903059 · Cited by 331 · see citing works

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100551108 · Cited by 312 · see citing works

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

Drobits, B., Holcmann, M., Amberg, N., Swiecki, M. K., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61034 · Cited by 295 · see citing works

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

Dardalhon, V., Anderson, A. C., Kármán, J., Apétoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278 · see citing works

Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via l -Arginine Metabolism

Norian, L. A., Rodrı́guez, P. C., O’Mara, L. A., Zabaleta, J., Ochoa, A. C., Cella, M., & Allen, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2826 · Cited by 270 · see citing works

Fen1 mutations result in autoimmunity, chronic inflammation and cancers

Zheng, L., Dai, H., Zhou, M., Li, M., Singh, P., Qiu, J., Tsark, W. M. K., Huang, Q. M., Kernstine, K. H., Zhang, X., et al. (2007) · Nature Medicine · doi:10.1038/nm1599 · Cited by 246 · see citing works

Coupling and Uncoupling of Tumor Immunity and Autoimmunity

Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins, W. G., Blachère, N. E., Dyall, R., Lewis, J. J., & Houghton, A. N. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1717 · Cited by 238 · see citing works

T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface

Cao, E., Zang, X., Ramagopal, U. A., Mukhopadhaya, A., Fedorov, A. A., Fedorov, E. V., Zencheck, W. D., Lary, J. W., Cole, J. L., Deng, H., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.016 · Cited by 228 · see citing works

Structures of T Cell Immunoglobulin Mucin Protein 4 Show a Metal-Ion-Dependent Ligand Binding Site where Phosphatidylserine Binds

Santiago, C. A., Ballesteros, Á., Martínez‐Muñoz, L., Mellado, M., Kaplan, G. G., Freeman, G. J., & Casasnovas, J. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.008 · Cited by 224 · see citing works

Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions

Nagahara, K., Arikawa, T., Oomizu, S., Kontani, K., Nobumoto, A., Tateno, H., Watanabe, K., Niki, T., Katoh, S., Miyake, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7660 · Cited by 207 · see citing works

Tim3 binding to galectin-9 stimulates antimicrobial immunity

Jayaraman, P., Sada‐Ovalle, I., Beladi, S., Anderson, A. C., Dardalhon, V., Hotta, C., Kuchroo, V. K., & Behar, S. M. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100687 · Cited by 198 · see citing works

Natural immunity to cancer in humans

Bindea, G., Mlecnik, B., Fridman, W. H., Pagès, F., & Galon, J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.006 · Cited by 192 · see citing works

New roles for TIM family members in immune regulation

Kuchroo, V. K., Dardalhon, V., Xiao, S., & Anderson, A. C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2366 · Cited by 131 · see citing works

The Ras–PI3K Signaling Pathway Is Involved in Clathrin-Independent Endocytosis and the Internalization of Influenza Viruses

Fujioka, Y., Tsuda, M., Hattori, T., Sasaki, J., Sasaki, T., Miyazaki, T., & Ohba, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016324 · Cited by 77 · see citing works

Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice

Nobumoto, A., Oomizu, S., Arikawa, T., Katoh, S., Nagahara, K., Miyake, M., Nishi, N., Takeshita, K., Niki, T., Yamauchi, A., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.09.014 · Cited by 66 · see citing works

High Mobility Group Protein-B1 Interacts with Sterol Regulatory Element-binding Proteins to Enhance Their DNA Binding

Najima, Y., Yahagi, N., Takeuchi, Y., Matsuzaka, T., Sekiya, M., Nakagawa, Y., Amemiya-Kudo, M., Okazaki, H., Okazaki, S., Tamura, Y., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414549200 · Cited by 47 · see citing works

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid–immunoglobulin complexes in humans

Lin, Y., Zhang, L., Cai, A., Lee, M. N., Zhang, W., Neuberg, D. S., Canning, C. M., Soiffer, R. J., Alyea, E. P., Ritz, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44581 · Cited by 18 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

Immunogenic cell death and DAMPs in cancer therapy

Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · see citing works

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Dendritic cells in cancer immunology and immunotherapy

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,594 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,384 · see citing works

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 1,151 · see citing works

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,151 · see citing works

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works

TIM3 comes of age as an inhibitory receptor

Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959 · see citing works

Harnessing innate immunity in cancer therapy

Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957 · see citing works

HMGB1 in health and disease

Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956 · see citing works

Targeting immunogenic cell death in cancer

Ahmed, A. S., & Tait, S. W. G. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12851 · Cited by 942 · see citing works

Dendritic Cells and Cancer Immunity

Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 896 · see citing works

The complex role of tumor-infiltrating macrophages

Christofides, A., Strauss, L., Yeo, A. T., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 869 · see citing works

Tim‐3 and its role in regulating anti‐tumor immunity

Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856 · see citing works

Consensus guidelines for the detection of immunogenic cell death

Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832 · see citing works

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer

Birge, R. B., Boeltz, S., Kumar, S., Carlson, J., Wanderley, J. L. M., Calianese, D. C., Barcinski, M. A., Brekken, R. A., Huang, X., Hutchins, J., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.11 · Cited by 731 · see citing works

Dendritic cell subsets in cancer immunity and tumor antigen sensing

Prete, A. D., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 663 · see citing works

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 602 · see citing works

Innate Immune Recognition of Cancer

Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 569 · see citing works

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Sivori, S., Vacca, P., Zotto, G. D., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 557 · see citing works

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 547 · see citing works

Immune checkpoints and their inhibition in cancer and infectious diseases

Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541 · see citing works

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Nakamura, K., & Smyth, M. J. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 521 · see citing works

HMGB1 in Cancer: Good, Bad, or Both?

Kang, R., Zhang, Q., Zeh, H. J., Lotze, M. T., & Tang, D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0495 · Cited by 496 · see citing works

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 489 · see citing works

Dendritic Cells and Their Role in Immunotherapy

Gardner, A., Pulido, Á. D. M., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485 · see citing works

Damage-associated molecular patterns in cancer: a double-edged sword

Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 483 · see citing works

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

Kim, J. E., Patel, M. A., Mangraviti, A., Kim, E. S., Theodros, D., Velarde, E., Liu, A., Sankey, E. W., Tam, A. J., Xu, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1535 · Cited by 465 · see citing works

Reversing T-cell Dysfunction and Exhaustion in Cancer

Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462 · see citing works

HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins

Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455 · see citing works

Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 448 · see citing works

Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis

Janco, J. M. T., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403134 · Cited by 440 · see citing works

Alarmins and immunity

Yang, D., Han, Z., & Oppenheim, J. J. (2017) · Immunological Reviews · doi:10.1111/imr.12577 · Cited by 412 · see citing works

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Garg, A. D., Galluzzi, L., Apétoh, L., Baert, T., Birge, R. B., Pedro, J. M. B., Breckpot, K., Brough, D., Chaurio, R. A., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 409 · see citing works

Innate immune signaling and regulation in cancer immunotherapy

Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408 · see citing works

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 404 · see citing works

Dendritic cells as orchestrators of anticancer immunity and immunotherapy

Heras‐Murillo, I., Adán‐Barrientos, I., Galán, M. Á., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 403 · see citing works

Tim-3 finds its place in the cancer immunotherapy landscape

Acharya, N., Sabatos-Peyton, C. A., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 397 · see citing works

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

Dudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 394 · see citing works

TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer

de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388 · see citing works

The multifunctional protein HMGB1: 50 years of discovery

Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00894-6 · Cited by 387 · see citing works

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Dixon, K. O., Tabaka, M., Schramm, M. A., Xiao, S., Tang, R., Dionne, D. A., Anderson, A. C., Rozenblatt–Rosen, O., Regev, A., & Kuchroo, V. K. (2021) · Nature · doi:10.1038/s41586-021-03626-9 · Cited by 371 · see citing works

High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule

Yang, H., Wang, H., Chavan, S. S., & Andersson, U. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00087 · Cited by 360 · see citing works

DAMPs, MAMPs, and NAMPs in plant innate immunity

Choi, H. W., & Klessig, D. F. (2016) · BMC Plant Biology · doi:10.1186/s12870-016-0921-2 · Cited by 356 · see citing works

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

Inoue, H., & Tani, K. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.84 · Cited by 352 · see citing works

T Cell Dysfunction in Cancer Immunity and Immunotherapy

Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 338 · see citing works

Cell death in pancreatic cancer: from pathogenesis to therapy

Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 339 · see citing works

High‐mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair

Bianchi, M. E., Crippa, M. P., Manfredi, A. A., Mezzapelle, R., Rovere, P. Q., & Vénéreau, E. (2017) · Immunological Reviews · doi:10.1111/imr.12601 · Cited by 327 · see citing works

Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape

Anderson, A. C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0039 · Cited by 302 · see citing works

Role of nonresolving inflammation in hepatocellular carcinoma development and progression

Yu, L., Yan, L., & Wang, H. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 302 · see citing works

Many faces of DAMPs in cancer therapy

Krysko, O., Aaes, T. L., Bachert, C., Vandenabeele, P., & Krysko, D. V. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.156 · Cited by 295 · see citing works

Antitumor effects of immunity-enhancing traditional Chinese medicine

Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 287 · see citing works

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation

Joller, N., Anderson, A. C., & Kuchroo, V. K. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.010 · Cited by 287 · see citing works

ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses

Garg, A. D., & Agostinis, P. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c3pp50333j · Cited by 276 · see citing works

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

Pulido, Á. D. M., Hänggi, K., Celias, D. P., Gardner, A., Li, J., Bittencourt, B. M. B., Mohamed, E. T., Trillo-Tinoco, J., Osunmakinde, O., Peña, R. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.019 · Cited by 272 · see citing works

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

Sánchez-Paulete, A. R., Teijeira, Á., Cueto, F. J., Garasa, S., Perez‐Gracia, J. L., Sánchez-Arráez, Á., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267 · see citing works

An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases

Liu, Y., Crowe, W. N., Wang, L., Lu, Y., Petty, W. J., Habib, A. A., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13094-5 · Cited by 255 · see citing works

Trial watch

Vacchelli, E., Vitale, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Cremer, I., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 246 · see citing works

Immunogenic cell death

Garg, A. D., Dudek-Perić, A. M., Romano, E., & Agostinis, P. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150061pa · Cited by 244 · see citing works

HMGB1 as biomarker and drug target

Vénéreau, E., Leo, F. D., Mezzapelle, R., Careccia, G., Musco, G., & Bianchi, M. E. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.031 · Cited by 240 · see citing works

Tumor-infiltrating dendritic cell states are conserved across solid human cancers

Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M., & Pittet, M. J. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200264 · Cited by 240 · see citing works

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

Du, W., Yang, M., Turner, A., Xu, C., Ferris, R. L., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 237 · see citing works

TIM-3, a promising target for cancer immunotherapy

He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235 · see citing works

Exploiting innate immunity for cancer immunotherapy

Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 236 · see citing works

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies

Yuan, S., Liu, Z., Xu, Z., Liu, J., & Zhang, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00920-3 · Cited by 228 · see citing works

Danger signalling during cancer cell death: origins, plasticity and regulation

Garg, A. D., Martin, S., Gołąb, J., & Agostinis, P. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.48 · Cited by 225 · see citing works

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

Lee, Y., Shin, J. H., Longmire, M. R., Wang, H., Kohrt, H. E. K., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 221 · see citing works

TIM-3: An update on immunotherapy

Zhao, L., Cheng, S., Fan, L., Zhang, B., & Xu, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107933 · Cited by 219 · see citing works

The role of macrophages polarization in sepsis-induced acute lung injury

Wang, Z., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1209438 · Cited by 219 · see citing works

A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity

Kumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 217 · see citing works

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma

Granier, C., Dariane, C., Combe, P., Verkarre, V., Urien, S., Badoual, C., Roussel, H., Mandavit, M., Ravel, P., Sibony, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0274 · Cited by 215 · see citing works

Killers 2.0: NK cell therapies at the forefront of cancer control

Hodgins, J. J., Khan, S., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 213 · see citing works

T cell exhaustion: from pathophysiological basics to tumor immunotherapy

Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

Han, G., Chen, G., Shen, B., & Li, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00449 · Cited by 198 · see citing works

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Ma, J., Ramachandran, M., Jin, C., Quijano‐Rubio, C., Martikainen, M. W., Yu, D., & Essand, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2236-3 · Cited by 198 · see citing works

The tumor microenvironment’s role in the response to immune checkpoint blockade

Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 203 · see citing works

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

Mercier, I. L., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 196 · see citing works

Strange attractors: DAMPs and autophagy link tumor cell death and immunity

Hou, W., Zhang, Q., Yan, Z., Chen, R., Zeh, H. J., Kang, R., Lotze, M. T., & Tang, D. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.493 · Cited by 194 · see citing works

The Dendritic Cell Response to Classic, Emerging, and Homeostatic Danger Signals. Implications for Autoimmunity

Gallo, P. M., & Gallucci, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00138 · Cited by 193 · see citing works

Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results

Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189 · see citing works

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

Pesce, S., Greppi, M., Grossi, F., Zotto, G. D., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 188 · see citing works

High‐mobility group box‐1 in sterile inflammation

Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187 · see citing works

Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling

Paudel, Y. N., Angelopoulou, E., Piperi, C., Balasubramaniam, V. R. M. T., Othman, I., & Shaikh, M. F. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172487 · Cited by 178 · see citing works

Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets

Gutiérrez-Martínez, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00363 · Cited by 177 · see citing works

The Role of Chronic Inflammation in the Development of Breast Cancer

Danforth, D. N. (2021) · Cancers · doi:10.3390/cancers13153918 · Cited by 173 · see citing works

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

Wu, B., Shi, X., Jiang, M., & Liu, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01748-4 · Cited by 173 · see citing works

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications

Fucikova, J. P., Palová-Jelínková, L., Bartůňková, J., & Špíšek, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02393 · Cited by 172 · see citing works

Activation of immune signals during organ transplantation

Li, Q., & Lan, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01377-9 · Cited by 173 · see citing works

Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion

Ferris, R. L., Lu, B., & Kane, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 169 · see citing works

Necroptosis in Immuno-Oncology and Cancer Immunotherapy

Sprooten, J., Wijngaert, P. D., Vanmeerbeek, I., Martin, S., Vangheluwe, P., Schlenner, S., Krysko, D. V., Parys, J. B., Bultynck, G., Vandenabeele, P., et al. (2020) · Cells · doi:10.3390/cells9081823 · Cited by 169 · see citing works

Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis

Jin, Q., Zhu, W., Zhu, J., Zhu, J., Shen, J., Liu, Z., Yang, Y., & Chen, Q. (2021) · Advanced Materials · doi:10.1002/adma.202007557 · Cited by 169 · see citing works

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion

Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 166 · see citing works

Immunological Significance of HMGB1 Post-Translational Modification and Redox Biology

Kwak, M. S., Kim, H. S., Lee, B., Kim, Y. H., Son, M., & Shin, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01189 · Cited by 166 · see citing works

The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy

Kandel, S., Adhikary, P., Li, G., & Cheng, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.011 · Cited by 166 · see citing works

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 165 · see citing works

Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms

Demoulin, S., Herfs, M. F., Delvenne, P., & Hubert, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812397 · Cited by 162 · see citing works

Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer

Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159 · see citing works

Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors

Patel, J. M., Bozeman, E. N., & Selvaraj, P. (2012) · Immunotherapy · doi:10.2217/imt.12.126 · Cited by 45 · see citing works

Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment

Jinushi, M. (2012) · OncoImmunology · doi:10.4161/onci.21681 · Cited by 6 · see citing works

A Dendritic Cell-Derived Receptor Counteracts Antitumor Immunity

(2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2012-123

Tumor immunity times out: TIM-3 and HMGB1

Tang, D., & Lotze, M. T. (2012) · Nature Immunology · doi:10.1038/ni.2396 · Cited by 116 · see citing works

TIM3 suppresses antitumour DCs

Alderton, G. K. (2012) · Nature reviews. Immunology · doi:10.1038/nri3288 · Cited by 4 · see citing works